Advertisement
Screener

ROIVANT SCIENCES LTD. (ROIV) Current Income Tax Expense (Benefit)

ROIVANT SCIENCES LTD. Current Income Tax Expense (Benefit)

ROIVANT SCIENCES LTD. (ROIV) reported Current Income Tax Expense (Benefit) of $133.33 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.

Financial Statements › Expense Statement › Income Tax

us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-05-20

  • ROIVANT SCIENCES LTD. current income tax expense (benefit) for fiscal 2026 was $133.33M, a 176.77% increase from fiscal 2025.
  • ROIVANT SCIENCES LTD. current income tax expense (benefit) for fiscal 2025 was $48.17M, a 124.03% increase from fiscal 2024.
  • ROIVANT SCIENCES LTD. current income tax expense (benefit) for fiscal 2024 was $21.50M, a 426.78% increase from fiscal 2023.
  • ROIVANT SCIENCES LTD. current income tax expense (benefit) for fiscal 2023 was $4.08M, a 1006.23% increase from fiscal 2022.
Period endCurrent Income Tax Expense (Benefit) 12 monthCurrent Income Tax Expense (Benefit) 12 month as first filed
2026-03-31$133.33M
10-K · filed 2026-05-20
2025-03-31$48.17M
10-K · filed 2026-05-20
2024-03-31$21.50M
10-K · filed 2026-05-20
$22.22M
10-K · filed 2024-05-30
2023-03-31$4.08M
10-K · filed 2025-05-29
$5.19M
10-K · filed 2023-06-28
2022-03-31$369.00K
10-K · filed 2023-06-28
2021-03-31$1.69M
10-K · filed 2022-06-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSMED Inc (INSM)United States$26.566B-26.60
Zoetis Inc. (ZTS)United States$29.045B11.38
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10